Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial.
about
Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedemaRecent developments in laser treatment of diabetic retinopathyLong-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edemaCost-effectiveness of treatment of diabetic macular edema.Ranibizumab, verteporfin photodynamic therapy or observation for the treatment of myopic choroidal neovascularization: cost effectiveness in the UK.Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration.Ranibizumab: the first vascular endothelial growth factor inhibitor approved for the treatment of diabetic macular edema.Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective.Trends in the Care of Diabetic Macular Edema: Analysis of a National CohortCost of diabetic retinopathy and macular oedema in a population, an eight year follow upEstimation of the need for bilateral intravitreal anti-VEGF injections in clinical practice.What the comprehensive economics of blindness and visual impairment can help us understandCost-effectiveness of ocriplasmin for the treatment of vitreomacular traction and macular holeAnti-VEGF therapy for diabetic macular edema.Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial.Modelling the cost-effectiveness of adopting risk-stratified approaches to extended screening intervals in the national diabetic retinopathy screening programme in Scotland.Cost-effectiveness of treatments for diabetic macular oedema: should we pay more attention to the appraisal and reporting of economic evaluations?Treatment of diabetic maculopathy.
P2860
Q24202071-A3FC44F6-2D88-4771-B1D0-512C57B3F30DQ28084139-F0E30BF9-F16C-4ACB-80D1-637A5DE45DF2Q28292764-9AE9753C-A0EB-431C-8F04-A9012EF29F18Q33606611-FD24A17A-01AF-411C-B814-0527DBFE917BQ34410824-7F3A577E-8980-4FD9-8BB4-EA677F21B133Q34624487-70680163-9286-45B9-9942-013DC0192F19Q34711043-D073099B-F670-44CD-9E5A-40FBBA0F749BQ35592307-444C94FB-C72B-43A1-8E63-04EB5BE5F322Q35933773-D6157323-E377-40D0-8AC9-EC596D4BAFF3Q36095304-D1C7A3A4-3D30-4EF0-A0C6-DD684362F731Q36099741-86C368E9-B39D-48E7-B39B-75F8E86D8632Q36377687-7E1FAAF2-4C7B-44F5-925D-EA29678152E8Q37037822-A094C60C-42ED-4B5B-B6B4-865A01D6AA08Q38219571-76F0F372-EE78-4000-A807-7A418A551CF7Q38376964-ACA3D700-1FED-4983-8BE4-C2DB25F29B1CQ39867113-41676CDE-7107-42DD-91F6-F6F80A50374EQ48221657-4BAFDBB7-685C-439E-B82C-3764637DF069Q53645110-E8B27CB1-C6AC-4A7A-882E-7F8B1CC52416
P2860
Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Cost-effectiveness of ranibizu ...... idence from the RESTORE trial.
@ast
Cost-effectiveness of ranibizu ...... idence from the RESTORE trial.
@en
type
label
Cost-effectiveness of ranibizu ...... idence from the RESTORE trial.
@ast
Cost-effectiveness of ranibizu ...... idence from the RESTORE trial.
@en
prefLabel
Cost-effectiveness of ranibizu ...... idence from the RESTORE trial.
@ast
Cost-effectiveness of ranibizu ...... idence from the RESTORE trial.
@en
P2093
P2860
P1476
Cost-effectiveness of ranibizu ...... idence from the RESTORE trial.
@en
P2093
Henrietta Onwordi
Kerry Gairy
Lieven Annemans
Martin Knudsen
Meghan Gallagher
Rafiq Hasan
Simu Thomas
P2860
P304
P356
10.1136/BJOPHTHALMOL-2011-300726
P407
P577
2012-03-07T00:00:00Z